HIV/AIDS Therapy
HAART-resistant HIV strains susceptible to bleomycin
Published in AIDS Weekly, March 27th, 2006
According to a study from the Netherlands, "In this study we performed phenotypic assays to assess involvement of the cancer chemotherapeutic agent bleomycin (BLM) in replication inhibition of mutant HIV-1 viral strains.
"Three clinically relevant mutant HIV variants, including one containing the Q151M mutation conferring multinucleoside resistance, were equally as sensitive to BLM as the wild-type HXB2 strain."
"Long-term incubation of BLM with a wild-type HIV(Ba-L) strain did not alter the sensitivity of the strain to BLM (IC50 of BLM 0.64 mcM at the beginning...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2006-03-27)
More Articles from AIDS Weekly
- HIV/AIDS Epidemiology
Advanced HIV cases suggest large pool of undiagnosed HIV infections in Southeast Brazil - HIV/AIDS Pathogenesis
HIV-1 resistant strains acquired during primary infection fuel cellular reservoir - HIV/AIDS Pathogenesis
Neurovirulent genotypes progressively selected in SIV-infected brain - HIV/AIDS-Associated Dementia
HIV-infected leukocyte transmigration across blood-brain barrier enhanced by CCL2 - Blood Safety
HIV prevalence in donated blood reduced after enhanced education and selection process - Blood Safety
HIV risk-behavior reporting by blood donors increased with automated phone system - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
